OSTX OS Therapies Inc. Final Profit

Corporate emblem and logo of OS Therapies (OSTX)

OS Therapies Incorporated (OSTX) share price action is driven by the progress of osteosarcoma treatment trials, which triggered a sharp impulse on the chart. The company's monetary result currently stands at -0.04. Growth is based on the development of unique methods for combating pediatric metastases, although success is constrained by global patenting complexities and raw material logistics risks amid current geopolitics.

OSTX (OS Therapies Incorporated) Net Profit history from 08/02/2024 to 10/31/2026

Analytical breakdowns and data insights for company OS Therapies (OSTX)

- stock value and consensus price forecast:
Market Price OS Therapies, Inc.|OSTX - Price Target Chart
- market capitalization data:
Market Value OS Therapies, Inc.|OSTX - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share OS Therapies|OSTX - Book Capitalization|Market Cap to Net Assets Ratio ostherapies.com|OSTX - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital OS Therapies Incorporated|OSTX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital OS Therapies Inc.|OSTX - Company Aggregate Debts|Debts to Book Value OS Therapies, Inc.|OSTX - Company Long-Term Debt|Short-Term Debt OS Therapies|Interim Coverage Ratio ostherapies.com
- net income and valuation multiples indicators:
OSTX - Net Income
Fundamental valuation:OSTX OS Therapies, Inc.
Manufactured product of OS Therapies Inc.

For OS Therapies Incorporated (OSTX), which is developing drugs against rare solid tumors, this metric reflects the efficiency of monetizing innovations during an active growth phase. An analysis of the company's operating profit allows for an assessment of the difference between revenue and total operating expenses, helping investors detect financial risks in a timely manner or confirm the business's ability to generate a sustainable cash flow.

Main competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Company Net Income Accuray Incorporated (ARAY)|SLS - Company Net Income|Company Net Income Actuate Therapeutics ACTU|Net Financial Result Citius Oncology Inc. (CTOR)|HURA: Net Income|Final Profit TARA (Protara Tx)|FATE (Fate Therapeutics, Inc.) - Net Income|WHWK: Profit After Payment of Taxes|TCRX (TScan Therapeutics Inc) - Net Profit|CSBR: Final Profit|Net Profit XBIT|CVM - Company Net Income|Company Net Income Radiopharm Theranostics Limited RADX|Final Profit ARTV|Adlai Nortye Limited - Net Profit|VERU - Net Profit|Tempest Tx (TPST) - Company Net Income|Profit After Tax XLO (Xilio Therapeutics)|RENB (Renovaro Biosciences) - Net Profit|Mural Bio (MURA) - Net Financial Result|Net Profit KAPA|OKUR - Company Net Income|Company Net Income CytoMed Therapeutics Limited GDTC|Net Financial Result Curis Inc. (CRIS)|APLM: Net Income|Final Profit THAR (tharimmune.com)|ADVB: Net Profit|GNPX - Net Financial Result|Company Net Income Calidi Biotherapeutics Inc.|Company Profit SBFM (Sunshine Biopharma Inc.)|Net Profit XBIO|Net Income salariuspharma.com SLRX|Company Net Income Purple Biotech Ltd. PPBT|American Oncology Network Inc (AONC) - Company Net Income|BGNE - Company Net Income|Final Profit CKPT (Checkpoint Therapeutics Inc)|Elevation Oncology, Inc. (ELEV) - Company Net Income|Profit After Tax ICAD (iCAD)|Company Net Income Ikena Oncology Inc.|Company Net Income Notable Labs Ltd NTBL|Company Net Income Viracta Therapeutics (VIRX)|MOR (MorphoSys Corporation) - Final Profit|Net Profit NAYA (NAYA Biosciences)|Net Profit ascentage.com AAPGV